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 Abstract 
Objectives: The anti-Wa antibody found in systemic sclerosis patients reacts with a transfer RNA 
(tRNA)-associated 48-kDa protein and immunoprecipitates several tRNAs. We investigated the Wa 
antigen and its binding to tRNA species. Methods: We performed molecular cloning of the Wa 
antigen and made its recombinant protein. To investigate Wa antigen distribution in the cell, we 
performed an indirect immunofluorescence study. To determine the Wa-bound tRNA species, we 
performed a reverse transcription (RT)-polymerase chain reaction (PCR) using the RNAs 
immunoprecipitated by anti-Wa antibody as templates, and synthetic primers of mammalian tRNA 
sequences. To clarify the tissue expression of Wa antigen, we performed quantitative and 
semi-quantitative PCR of the cDNA. Results: We demonstrated that the Wa antigen was identical to 
NEFA (DNA binding/EF-hand/acidic amino acid rich region), otherwise known as nucleobindin-2. A 
full-length and an alternative splice variant cDNA lacking exon 11 were isolated by cloning NEFA 
cDNA. Anti-Wa-positive sera stained both the nucleus and cytoplasm of HEp-2 cells. RT-PCR 
suggested that Wa binds at least six tRNA species. In human tissues, NEFA is expressed 
predominantly in exocrine glands. Conclusions: We have demonstrated that the Wa antigen is NEFA 
or nucleobindin-2, which binds the specific tRNA species, and is distributed in specific human tissues.  
3 
Introduction 
In connective tissue diseases, autoantibodies often recognize cellular components of both the 
nucleus and cytoplasm. These target autoantigens are frequently associated with either nucleic acids 
themselves or with proteins binding to nucleic acids. The anti-Wa antibody is a transfer RNA 
(tRNA)-associated antibody that was reported in 1991 [1]. It was named after a patient with systemic 
sclerosis (SSc) in whom the antibody was first found. It reacts with a 48-kDa protein that binds 
several unidentified tRNAs. The electrophoretic pattern of the tRNAs immunoprecipitated by the 
anti-Wa antibody is different from the patterns of other known tRNA-associated antibodies, such as 
those binding anti-aminoacyl tRNA synthetases.  
In this study, we demonstrate that the Wa autoantigen is identical to NEFA or nucleobindin-2 [2]. 
NEFA (DNA binding, EF-hand, acidic amino acid-rich region) was named by Barnikol-Watanabe et al. 
[2]. Its molecular weight is 47.713 kDa [2, 3], which is the same as that of the Wa antigen [1]. NEFA 
has homology with nucleobindin [4], and is therefore also known as nucleobindin-2. NEFA has a 
basic amino acid-rich region and is thought to bind to DNA, although there is no direct evidence for 
this, nor is there any direct evidence for its binding to RNA. 
Here, we confirm that NEFA is identical to the Wa antigen and that it binds several tRNAs. It may 
be involved in regulating the secretion of proteins, as well as being involved with calcium metabolism, 
and could affect protein translation systems and feeding behavior via tRNAs. 
 
Materials and methods 
Sera and antibodies 
The prototype serum containing anti-Wa antibody was a gift from Dr. Hajime Yamagata, National 
Hospital Organization, Murayama Medical Center, Tokyo, Japan. Other anti-Wa-positive sera, as 
described previously [1], were also used. Permission for the use of these sera was obtained from the 
internal review board of each institution. All sera were stored at -20°C until use. 
Rabbit anti-NEFA serum was produced by inoculating a rabbit (Japanese White) by Scrum (Tokyo, 
Japan) with recombinant NEFA. Fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG 
was purchased from Cappel (West Chester, PA, USA). 
Molecular cloning of Wa-encoded cDNA 
Cloning of cDNA for the Wa antigen was performed using a lambda gt11 cDNA library constructed 
from human liver mRNA (Clontech, Palo Alto, CA, USA) and the anti-Wa prototype serum as the 
probe, as described by Young and Davis [5]. Positive clones were picked and purified repeatedly until 
all progeny plaques were positive. cDNA inserts isolated from positive clones were ligated into 
pUC118 and the sequence of the cDNA insert in the plasmid was determined. Detailed homologies of 
nucleotide and deduced amino acid sequences were analyzed using NCBI BLAST 
(http://www.ncbi.nlm.nih.gov/blast). 
Affinity purification of anti-Wa antibody 
Affinity-purified anti-Wa antibody reacted with recombinant proteins was obtained as previously 
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described [6]. Briefly, recombinant proteins from each positive clone were absorbed on a 
nitrocellulose (NC) filter (BA-85, Schleicher & Schuell, Dassel, Germany). The filter was incubated 
with the diluted anti-Wa prototype serum. After washes, antibodies were eluted from the filter-bound 
fusion proteins. 
RNA immunoprecipitation 
Ten microliters of sera containing anti-Wa antibody was mixed with 2 mg of Protein A-Sepharose 
CL-4B (Amersham Biosciences, Buckinghamshire, UK) in 500 µl IPP buffer (10 mM Tris-HCl, 500 
mM NaCl, 0.1% Nonidet P-40, pH 8.0) and incubated at 4°C for 2 h. The Sepharose particles were 
then washed three times with IPP buffer and incubated with extracts from 6×106 sonicated HeLa cells 
per sample in 700 µl NET-2 buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% Nonidet P-40, pH 7.5) at 
4°C for 2 h. Following five washes with the NET-2 buffer, nucleic acids were extracted from the 
immunoprecipitates with phenol/chloroform/isoamyl alcohol (50:50:1) and precipitated with ethanol. 
They were separated by 8 M urea-10% polyacrylamide gel electrophoresis and visualized by silver 
staining using a Bio-Rad Silver Stain kit (Bio-Rad Laboratories, Hercules, CA, USA) [7]. 
Immunoblotting with anti-Wa-positive sera 
Cloned phages were infected into Escherichia coli Y1089 to develop lysogens. Fusion proteins 
were prepared, separated on sodium dodecylsulfate (SDS)-7.5% polyacrylamide slab gel, and 
transferred to an NC membrane. After blocking with 2% skim milk, patient sera were preabsorbed 
with E. coli lysates (1:100), and then goat anti-human IgG conjugated to alkaline phosphatase (1:500) 
(Promega, Madison, WI, USA) and NBT/BCIP (Promega) were used for immunoblotting. 
Preparation of recombinant NEFA 
cDNAs encoding NEFA were prepared from HeLa cell messenger RNA (mRNA) by reverse 
transcription (RT)-polymerase chain reaction (PCR) according to the published sequence of NEFA [2], 
and cloned using a TOPO-XL PCR Cloning Kit (Invitrogen, Carlsbad, CA, USA). The products were 
verified by sequencing. NEFA cDNA was inserted into the pET151 plasmid using a Champion pET 
Directional TOPO Expression Kit (Invitrogen), expressed together with a His tag and a V5 epitope tag. 
Recombinant NEFA was expressed in E. coli (BL21 Star; Invitrogen) and purified via the His tag on 
BD TALON Superflow Resin (BD Biosciences, Mountain View, CA, USA). 
Protein immunoprecipitation 
Ten microliters of sera was mixed with 2 mg Protein A-Sepharose CL-4B in 500 µl IPP buffer and 
incubated at 4°C for 2 h. The Sepharose particles were washed three times with IPP buffer and then 
incubated with sonicated E. coli extracts containing recombinant NEFA at 4°C for 2 h. The Sepharose 
particles were washed five times with IPP buffer. Immunoprecipitates were separated by SDS-10% 
polyacrylamide gel electrophoresis (SDS-PAGE), and recombinant NEFA was visualized by western 
blotting using the His Western Kit (BD Biosciences) according to the manufacturer’s instructions. 
Indirect immunofluorescence 
HEp-2 cells on slides (FLUORO HEPANA test, MBL Laboratories, Aichi, Japan) were stained with 
anti-Wa-positive sera or normal human serum according to the manufacturer’s protocol. When the 
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cells were stained with rabbit anti-NEFA sera, FITC-conjugated goat anti-rabbit whole IgG (Cappel) 
was used instead of the FITC-conjugated goat anti-human IgG from the kit. These slides were then 
examined under a fluorescence microscope (AxioVert200; Carl Zeiss, Göttingen, Germany). 
Reverse transcription (RT)-PCR of tRNAs 
Twenty-two sets of primers were synthesized by reference to known mammalian tRNAs. These 
primer sets were predesigned and made by Sigma-Genosys (Hokkaido, Japan). tRNAs 
immunoprecipitated by autoantibodies were used as templates, and total RNA from HeLa cells as the 
positive control. RT-PCR was performed using One Step RNA PCR Kits (TaKaRa, Shiga, Japan) 
according to the manufacturer’s protocol. PCR products were separated on 10% native 
polyacrylamide gels, stained with ethidium bromide, and visualized by UV light. 
Quantitative real-time PCR (qPCR) 
To examine the distribution of NEFA in various tissues and organs, qPCR was performed. Primer 
sets for wild-type and splice variant NEFA were designed by reference to the cloned NEFA cDNAs. 
The specificity of the primer sets was verified by PCR, using the cloned NEFA cDNA as templates. 
Quantitative PCR was performed-using Human MTC Panel I and II (Clontech) human tissue cDNA 
templates-with SYBR Premix Ex Taq (TaKaRa) on an Applied Biosystems 7500 real-time PCR 
system (Applied Biosystems, Carlsbad, CA, USA). Quantification was performed with the cloned 
NEFA cDNAs after normalization against glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Semi-quantitative PCR 
Primer sets were designed on both sides of exon 11 (lacking in the splice variant NEFA) by 
reference to the cloned NEFA cDNA. Semi-quantitative PCR was performed-using Human 
Rapid-Scan (OriGene, Rockville, MD, USA) as human tissue cDNA templates-with La Taq (TaKaRa). 
The PCR products were separated on 2% agarose gels and stained with ethidium bromide. 
 
Results 
Cloning and sequencing of cDNA encoding the Wa antigen 
Using the anti-Wa prototype serum as a probe, we screened 106 clones from the lambda gt11 human 
cDNA library and isolated 10 positive clones, termed Wa-1 to Wa-10. We examined whether 
affinity-purified antibodies from these 10 clones could immunoprecipitate tRNA. Affinity-purified 
antibody from clone Wa-1, as well as anti-Wa serum, immunoprecipitated tRNA, so we assumed that 
Wa-1 cDNA encoded the Wa antigen (Fig. 1a). The affinity-purified antibody from clone Wa-2 
immunoprecipitated smeary nucleic acid components, including tRNA, so Wa-2 was also used for the 
further study. Using fusion proteins of Wa-1, Wa-2, and β-galactosidase (96 kD), we performed 
immunoblot studies with the prototype anti-Wa serum, 5 anti-Wa-positive sera, and a normal human 
serum. The Wa-1 fusion protein was recognized by the prototype anti-Wa serum and all five 
Wa-positive sera, whereas the Wa-2 fusion protein was recognized only by the prototype anti-Wa 
serum (Fig. 1b). These data indicated that the Wa-1 clone corresponded to the Wa antigen. The cDNA 
inserts obtained from recombinant clone phages were sequenced, and a homology search in NCBI 
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BLAST revealed that the nucleotide sequence and deduced amino acid sequence of Wa-1 insert cDNA 
were completely identical to those of partial human NEFA protein at nucleotide sequence positions 
(np) 434-1200. 
Confirmation that Wa and NEFA are identical 
NEFA cDNAs were cloned from HeLa cell mRNA and used to produce recombinant NEFA protein. 
We obtained two types of cDNAs from this cloning, one of which encoded the target-length NEFA 
and the other, which encoded a 90-bp-shorter variant. A homology search with the 90-bp-deleted 
sequence in NCBI BLAST identified a sequence on human chromosome 11. We compared NEFA 
cDNA and chromosome 11, and found that NEFA cDNA consists of 14 exons (Fig. 1c), in agreement 
with a previous report [2]. The shorter splice variant lacked exon 11 (np 1132-1221), which encodes 
one of the two EF-hands. We constructed a recombinant wild-type NEFA (rNEFAw) with a His tag 
and a V5 epitope tag, using a Champion pET Directional TOPO Expression Kit (Invitrogen). By 
direct western blotting, rNEFAw after SDS-PAGE separation was found not to react with anti-Wa sera 
(data not shown). Therefore, we carried out anti-Wa sera immunoprecipitations of sonicated E. coli 
extracts expressing rNEFAw (Fig. 2a). All six anti-Wa-containing sera reacted with rNEFAw but not 
with anti-Jo-1 serum or normal human serum. 
We produced hyperimmune anti-NEFA sera by inoculating two rabbits with purified rNEFAw. 
Using these hyperimmune anti-NEFA sera, the reactivity between NEFA and tRNA was verified by 
RNA-immunoprecipitation of HeLa cell extracts. The serum of one rabbit immunized with rNEFAw 
immunoprecipitated several tRNAs that were bound more weakly but appeared to be identical to the 
tRNAs recognized by anti-Wa sera (Fig. 2b). 
To investigate the distribution of Wa antigen and NEFA in the cell, an indirect immunofluorescence 
study was performed. We used sera apparently containing only anti-Wa antibody. We did not detect 
other known autoantibodies in these sera when testing by RNA and protein immunoprecipitation 
assays. Anti-Wa-positive sera stained both the nucleus and cytoplasm of HEp-2 cells (Fig. 2c). 
Anti-NEFA rabbit serum showed a similar staining pattern at the high dilution of 1:320. A lower 
dilution of 1:5 showed a characteristic perinuclear staining similar to that in the Golgi complex, which 
is consistent with the distribution of NEFA according to a previous report [8, 9]. One of the four 
anti-Wa sera also showed perinuclear staining similar to that in the Golgi complex. 
tRNA species associated with Wa/NEFA 
To determine the species of Wa-bound tRNAs, RT-PCR was performed using the RNAs 
immunoprecipitated with the anti-Wa or anti-NEFA antibody as templates, and synthetic primers of 22 
known mammalian tRNA sequences (Fig. 3a). We searched for human tRNA sequences in PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), and found 15 of 20 species of tRNAs at that time. Five 
human tRNA sequences (for cysteine, aspartic acid, glutamic acid, isoleucine, and tryptophan) could 
not be found and were therefore replaced by other mammalian tRNAs (rat, mouse, or bovine). 
Because each set of tRNA has many isotypes, one of each tRNA species was used arbitrarily. Glycine 
and arginine tRNAs had diverse sequences, and we selected two sequences for each tRNA species. All 
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tRNA species were successfully amplified by RT-PCR using HeLa cell total RNAs (Fig. 3bA), and the 
PCR products were verified by sequencing. RT-PCR products derived from RNA immunoprecipitated 
by anti-EJ (anti-glycyl-tRNA synthetase) showed two glycine tRNA bands, as expected (Fig. 3bB). 
With anti-Wa immunoprecipitated tRNAs, many species were amplified. Of these, tRNAs for arginine, 
glycine, histidine, methionine, lysine, and proline were easily detected even when the number of PCR 
cycles was reduced, strongly suggesting that these were the Wa-bound tRNAs (Fig. 3bC). The same 
species were amplified with anti-NEFA-immunoprecipitated tRNAs (Fig. 3bD). 
Tissue distribution of NEFA 
To establish the tissue expression of wild-type NEFA (NEFAw) and splice variant NEFA (NEFAsv), 
we performed quantitative and semi-quantitative PCR using human tissue cDNA panels. For qPCR of 
NEFA, 3’ primers were designed on the splice site of exon 11 in order to distinguish between NEFAw 
and NEFAsv (Fig. 4a). A primer set for NEFAw amplified its template cDNA, but not NEFAsv cDNA, 
and vice versa (data not shown). Human MTC Panel I and II (Clontech) were used as tissue cDNA 
templates and normalized against GAPDH cDNA (Fig. 4b). NEFA cDNA was detected in many 
tissues, with particularly strong expression observed in the pancreas, placenta, and testis. NEFAsv was 
expressed at a much lower level than the wild-type, but with a similar tissue distribution. For the 
semi-quantitative PCR of NEFA, primers were designed on both sides of exon 11, and these were thus 
able to distinguish between NEFAw cDNAs (260 bp) and NEFAsv cDNAs (170 bp) (Fig. 4a). Human 
Rapid-Scan (OriGene) was used as a source of tissue cDNA templates, normalized against β-actin 
cDNA and tested at four concentrations (×1000, ×100, ×10, ×1). Semi-quantitative PCR showed a 
distribution of NEFAw and NEFAsv similar to that shown by qPCR, particularly in the pancreas, 
placenta, and testis, and also in the salivary gland (Fig. 4c). 
 
Discussion 
The anti-Wa antibody was first reported in 1991 [1]. It was named after the SSc patient in whom 
the antibody was discovered. In the first report, the anti-Wa antibody was detected in the sera of 4 of 
130 SSc patients, but it was not detected in the sera of patients with other systemic autoimmune 
diseases or in the sera of healthy controls. In addition to its presence in some SSc patients, it was also 
reported in one Sjögren’s syndrome (SS) patient [10] and two polymyositis/dermatomyositis 
(PM/DM) patients [11]. The electrophoretic pattern of the tRNAs immunoprecipitated by anti-Wa 
antibody is different from that of other known tRNA-associated antibodies, such as those binding 
anti-aminoacyl tRNA synthetases in PM/DM. The anti-Wa antibody has been reported mainly in SSc, 
and the seven reported patients were all females, and out of them, in whom Raynaud’s phenomenon, 
interstitial lung disease, and cardiomegaly were found in 6, 4, and 3 patients, respectively. Two 
patients had SS as an associated disease and one of these two had anti-SS-A/Ro and anti-SS-B/La 
antibodies. The other patient had anti-Ki and anti-RNA polymerase antibodies [1, 12, 13]. The two 
myositic patients with the anti-Wa antibody were a male and a female and both showed shrinking 
interstitial lung disease, while the female patient showed mechanic’s hand [11], these being clinical 
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features associated with anti-aminoacyl tRNA synthetase antibodies in PM/DM [14, 15]. 
In the present study, we have demonstrated that the Wa autoantigen is identical to NEFA, otherwise 
known as nucleobindin-2. NEFA has a basic amino acid-rich region and is thought to bind to DNA via 
this domain [2]. We confirmed that NEFA is identical to the Wa antigen and that it binds several 
tRNAs, including those for arginine, glycine, histidine, methionine, lysine, and proline. The 
intracellular localization of NEFA differs in the different cell lines investigated. NEFA has been 
reported to be located in the cytomembrane and cytoplasm of the KM3 lymphoblastic leukemia cell 
line [2], the Golgi apparatus of HeLa cells [8, 9], and the endoplasmic reticulum and nuclear 
membrane of the mouse embryonal carcinoma line P19 [16]. We have shown in the present study that 
Wa/NEFA is expressed in both the nucleus and cytoplasm, in agreement with previous reports. 
The NEFA gene is located on chromosome 11 and consists of 14 exons [17, 18]. It was detected in a 
study of the locus responsible for Usher syndrome type 1c (located at 11p14-15.1), but no NEFA 
mutation could be found in these patients. The cloning of NEFA cDNA from HeLa cells enabled us to 
obtain a previously reported full-length cDNA and a novel 90-bp-shorter variant. The latter variant 
lacked exon 11, which encodes one of the two EF-hands at the C-terminal end. We could not 
demonstrate the expression of the variant NEFA protein or its binding ability with tRNA, but we 
found that its mRNA, like that of the wild-type full-length cDNA, was expressed in many tissues, 
albeit at a much lower level than the wild-type full-length cDNA. The variant NEFA may have 
binding ability with tRNA via the basic amino acid- rich region, but we could not demonstrate the 
binding ability of wild-type NEFA or the splice variant NEFA with recombinant proteins (data not 
shown). 
NEFA can bind two Ca2+ ions by means of the two EF-hands, but mutated NEFA with the EF-hand 
of the N-terminal side artificially deleted no longer binds Ca2+ [16, 19, 20]. Necdin (neurally 
differentiated embryonal carcinoma-derived protein) [16], TNFR1 (tumor necrosis factor receptor 1), 
and ARTS-1 (aminopeptidase regulator of TNFR1 shedding) [21] have been reported to bind NEFA. 
Necdin, which was discovered in murine embryonal carcinoma P19 cells that were caused to 
differentiate into postmitotic neurons, is also expressed in normal postmitotic neurons [22]. Necdin 
interacts with NEFA via two EF-hands [16]. Caffeine-evoked cytosolic Ca2+ levels are increased in 
cells over-expressing NEFA, and this phenomenon is enhanced by the co-expression of Necdin [16]. 
Exocrine stimulation increases cytoplasmic Ca2+ concentration in exocrine cells. 
NEFA binds to ARTS-1 and TNFR1 in a Ca2+-dependent manner [21]. TNFR1 is released via two 
different mechanisms: (1) proteolytic cleavage and shedding of the ectodomain from the cell surface; 
and (2) the release of full-length TNFR1 within exosome-like vesicles. The NEFA fragment, which 
contains the acidic region and part of the EF-hand of the C-terminal side, interacts with the ARTS-1 
protein. Both NEFA and ARTS-1 co-immunoprecipitate primarily with TNFR1, and the formation of 
this tripartite complex depends on Ca2+. The extracellular release of TNFR1 is reduced when NEFA is 
knocked down, and the release is also reduced by Ca2+ chelation. 
NEFA is predicted to be cleaved into three fragments by prohormone convertases [23, 24]. The 
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intracerebroventricular injection of NEFA or its N-terminal 82-amino-acid fragment lacking the signal 
peptide caused reduced feeding behavior in rats. This fragment was named nesfatin-1 
(NEFA/nucleobindin 2-encoded satiety- and fat-influencing protein). Other fragments generated by 
prohormone convertases, nesfatin-2 and nesfatin-3, as well as a NEFA mutant that could not be 
cleaved by prohormone convertases, did not decrease food intake. On the other hand, NEFA is cleaved 
by caspases at sites different from the prohormone convertase sites during apoptosis [24]. While 
nesfatin-1 was initially identified in hypothalamic nuclei, NEFA and nesfatin-1 are also expressed in 
peripheral tissues such as adipose tissue, gastric glands, the submucosal layer of the duodenum, 
pancreatic β-cells, and reproductive organs [25]. Nesfatin-1 enhances glucose-induced insulin 
secretion by promoting Ca2+ influx in mouse islet β-cells [26]. In our study, NEFA was associated 
with several tRNAs, including those for arginine, glycine, histidine, methionine, lysine, and proline, 
and possibly others. Interestingly, histidine, methionine, and lysine are essential amino acids that 
cannot be synthesized in the human body, while arginine, glycine, and proline are conditionally 
essential [27]. Thus, NEFA might monitor nutritional conditions by binding to aminoacyl or 
non-aminoacyl tRNAs and thereby influence the feeding behavior and immune responses mediated by 
nesfatin-1 or TNFR1, respectively. 
In summary, we have identified the species of tRNA binding with NEFA, as well as the NEFA 
splice variant lacking exon 11, and its distribution in human tissues. The physiological role of NEFA 
remains unclear, but, together with Ca2+, it may be involved in secretory systems and could affect 
protein translation and feeding behavior via tRNAs. 
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FIGURE LEGENDS 
Figure 1  
(a) Anti-Wa serum was affinity purified with recombinant proteins Wa-1 to Wa-10. RNA 
immunoprecipitation was then performed with each affinity-purified anti-Wa serum (lanes 1-10). 
Lane T: electrophoresis of total RNA. Lane C: no RNAs immunoprecipitated by normal human serum. 
(b) β-Galactosidase (lane 1), Wa-1 fusion protein (lane 2) and Wa-2 fusion protein (lane 3) were 
electroporated and immunoblotted with anti-Wa positive-sera (lane a-f) and normal human serum 
12 
(lane g). (c) NEFA (DNA binding/EF-hand/acidic amino acid rich region) cDNAs. Full-length (wild: 
w) cDNA and splice-variant (sv) cDNA lacking exon 11 were cloned from HeLa cell total cDNAs. 
Exons of NEFAw cDNA are shown as nucleotide sequence positions (n.p.). Specific regions of the 
NEFA protein are shown as amino acid sequence positions (a.p.).  
 
Figure 2  
(a) Immunoprecipitation of recombinant wild-type NEFA (rNEFAw) by anti-Wa antibody. rNEFAw 
was immunoprecipitated by sera and western-blotted by anti-His antibody. Anti-Wa sera (lanes 1-6), 
anti-Jo-1 serum (lane 7) and normal human serum (lane 8) are shown. (b) tRNAs immunoprecipitated 
by anti-NEFA antibody. Serum from a rabbit immunized with recombinant NEFA (lane R) or anti-Wa 
antibody (lane Wa) was used to immunoprecipitate several tRNAs. Anti-Wa serum in this assay 
contained anti-SS-A/Ro antibody and immunoprecipitated Y1-5 RNAs. Lane T: electrophoresis of 
total RNA. (c) (A to D) HEp-2 cells stained with four different anti-Wa-positive sera not containing 
any other antibodies. (E and F) HEp-2 cells stained with anti-NEFA antibody (Ab) diluted 1:320 or 
1:5. (G) HEp-2 cells stained with normal human serum. 
 
Figure 3  
(a) Transfer RNA sequences and primers. Anticodons are shown in bold characters. Primer positions 
are underlined. a Mouse tRNA. b Rat tRNA. c Bovine tRNA. (b) Reverse transcription-polymerase 
chain reaction (RT-PCR) performed with 22 sets of mammalian tRNA primers and HeLa cell total 
RNAs (A) or tRNAs immunoprecipitated by antibodies (B, C, D). (A) RT-PCR with HeLa cell total 
RNAs as template. (B) RT-PCR with tRNAs immunoprecipitated by anti-EJ (glycyl-tRNA synthetase) 
sera. (C) RT-PCR with anti-Wa-immunoprecipitated tRNAs. (D) RT-PCR with 
anti-NEFA-immunoprecipitated tRNAs.  
 
Figure 4  
(a) Positions of NEFA primers for quantitative and semi-quantitative PCR. A: Primer sequences for 
quantitative PCR. 3’ primers were designed for splice site (exon 11) in order to distinguish between 
NEFAw and splice variant NEFA (NEFAsv). The primer set for NEFAw amplified its template and not 
the NEFAsv cDNA template, and vice versa (data not shown). B: Primer sequences for 
semi-quantitative PCR. Primers were designed on both sides of exon 11, thus detecting both wild-type 
NEFA cDNAs (260 bp) and splice-variant NEFA cDNAs (170 bp). (b) Quantitative PCR of NEFA. 
Human MTC Panel I and II (Clontech) were used as templates and normalized against 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA. (c) Semi-quantitative PCR of NEFA. 
Human Rapid-Scan (OriGene) was used as a template, was normalized against β-actin cDNA, and 
used at four concentrations (×1000, ×100, ×10, ×1).  
 




